Navigation Links
CryoLife Conducts Surgeons Cardiac Allograft Symposium
Date:4/24/2008

ATLANTA, April 24 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that it is conducting the 2008 Cardiac Allograft Symposium at its corporate headquarters training facility in suburban Atlanta, GA, April 25-26. The program will focus on current clinical outcomes, indications and surgical techniques of aortic valve replacement utilizing aortic allografts and the CryoValve(R) SG pulmonary human heart valves.

"As leaders in human tissue transplantation and cardiac reconstruction, it is both an honor and a privilege to host this advanced surgical training at our state-of-the-art facility and laboratory," said Steven G. Anderson, president and chief executive officer of CryoLife, Inc. "We look forward to bringing together this eminent group of cardiovascular surgeons and offering them the opportunity to learn the newest surgical techniques utilizing human aortic valves and our recently FDA-cleared CryoValve SG pulmonary valve."

The symposium's distinguished faculty includes: John W. Brown, M.D., professor of cardiothoracic surgery, Indiana University School of Medicine, Indianapolis, Ind; Paul E. Stelzer, M.D., senior faculty, cardiothoracic surgery, Mount Sinai School of Medicine, New York, N.Y.; Craig R. Saunders, M.D., chairman of cardiothoracic surgery, Saint Barnabas Health Care System, Newark, N.J.; Kent E. Ward, M.D., associate professor of pediatric cardiology, University of Oklahoma Health Sciences Center, Oklahoma City, Okla; Kenton J. Zehr, M.D., professor of surgery, University of Pittsburgh Medical Center, Pittsburgh, Pa.; and Edward Nowicki, M.D., assistant head, clinical investigations, Heart & Vascular Institute, Cleveland Clinic, Cleveland, Ohio.

The program director is William F. Northrup, III, M.D., vice president, medical relations and education at CryoLife. Steven Goldstein, Ph.D., senior director, tissue technologies at CryoLife is also on the faculty. Some 20 surgeons from around the United States are expected to participate in the symposium.

About CryoLife, Inc.

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the United States and Canada. The Company recently received FDA clearance for the CryoValve(R) SG pulmonary human heart valve, processed using CryoLife's proprietary SynerGraft(R) Technology. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. Beginning May 1, 2008 CryoLife will distribute Hemostase MPH, a hemostatic agent, in much of the U.S. for use in cardiac and vascular surgery and in the United Kingdom and Germany for cardiac, vascular and general surgery, subject to certain exclusions. The Company also distributes the CryoLife-O'Brien(R) stentless porcine heart valve, which is CE marked for distribution within the European Community.

For additional information about the company, visit CryoLife's Web site: http://www.cryolife.com.

Media Contacts:

D. Ashley Lee Katie Brazel

Executive Vice President, Fleishman Hillard

Chief Financial Officer and Phone: 404-739-0150

Chief Operating Officer

Phone: 770-419-3355


'/>"/>
SOURCE CryoLife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CryoLife to Distribute FDA-approved Hemostatic Agent Under Private Label
2. CryoLife Closes on $15 Million Credit Facility with GE Healthcare Financial Services
3. CryoLife Announces Implant of First FDA-Cleared SynerGraft(R) Processed Human Pulmonary Heart Valve
4. CryoLife to Present at Roth Capital Partners 20th Annual Orange County (OC) Growth Stock Conference
5. CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Pulmonary Heart Valves
6. CryoLife Announces Release Date and Teleconference Call Details for the Fourth Quarter and Year End 2007 Financial Results
7. Cryolife Once Again Severely Maims an Innocent Knee Surgery Patient
8. CryoLife Responds to Inaccurate Assertions from Plaintiffs Attorney
9. CryoLife Announces Record Preservation Services and Product Revenues for 2007
10. CryoLife to Present at OneMedPlace Finance Forum
11. CryoLife to Present at 19th Annual Piper Jaffray Health Care Conference in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... MONICA, Calif. , June 23, 2016  The Prostate Cancer Foundation ... pioneer increasingly precise treatments and faster cures for prostate cancer. Members of the ... institutions across 15 countries. Read More About the Class ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report ... detail how a patient who developed lymphedema after being treated for breast cancer benefitted ... change the paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
Breaking Biology Technology:
(Date:6/20/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring announced that ... has secured the final acceptance by all three ... Access Systems (MAS) installed. Furthermore, Securus will have ... installed by October, 2016. MAS distinguishes between legitimate ...
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/1/2016)... 2016 Favorable Government Initiatives Coupled ... Criminal Identification to Boost Global Biometrics System Market Through ... Research report, " Global Biometrics Market By Type, ... Opportunities, 2011 - 2021", the global biometrics market is ... account of growing security concerns across various end use ...
Breaking Biology News(10 mins):